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Background
• Chronic hepatitis B virus (HBV) infection affects approximately 10% of HIV-
positive people in sub-Saharan Africa (SSA)1 and is an important risk factor for 
liver-related events and death.
• Due to high rates of losses to follow-up (LTFU) in African HIV clinics2, precise 
mortality estimates among cohorts of patients on antiretroviral therapy (ART) are 
scarce. 
Results
Table 1.  Demographic and clinical characteristics, by country 
• 263 HIV/HBV-coinfected patients were included. Patients in Mozambique were 
more likely to be female, to have moderate or severe anaemia (<11g/dl for men 
and < 10g/dl for women), elevated ALT levels and higher CD4 cell counts (Table 
1). 
• At 1 year, after the systematic tracing of patients LTFU, vital status was unknown 
in only one patient (1.3%) in Mozambique and 7 patients (3.8%) in Zambia. 
• The MPR in patients with one year follow up was 69% (95% CI 20.3-89.3) in 
Mozambique and 97% (95% CI 97.8-100) in Zambia (p<0.01). 
Figure 1. Survival of HIV/Hepatitis B-coinfected patients on ART, by country
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Objectives
• To compare one-year mortality of HIV/HBV-coinfected patients on tenofovir
(TDF)-containing ART between rural and urban primary care clinics in southern 
Africa after the systematic tracing of patients LTFU.
• To assess risk factors for all cause mortality.
Methods
Study Population and Inclusion Criteria
• We included  HIV/HBV coinfected adults (>16 years)  initiating TDF-containing 
ART at two urban clinics in Lusaka, Zambia, and three rural clinics in northern 
Mozambique between May 2013 and July 2015.
Procedures
• HBV infection was assessed using HBsAg rapid tests (Determine®).
• Quantitative real-time PCR for HBV viral load was performed using the COBAS 
Ampliprep/TaqMan System and HBV sequencing according to an in-house 
protocol1. 
• Medication possession ratio (MPR, calculated as days of ART possession/ 365 
days*100) was used as a proxy for treatment adherence3.  
• All patients LTFU (>3 months without a clinical visit) were traced by phone and 
home visits for ascertainment of vital status. 
Statistical analyses 
• Baseline characteristics were compared between treatment settings using 
Fisher`s exact test and Wilcoxon rank sum tests. 
• Mortality and associated risk factors were assessed using multivariable Cox 
proportional hazards regression.
Table 2. Risk factors for mortality
• One-year mortality was 16 % in Mozambique and 8% in Zambia (p=0.06) (Fig. 1). 
• In adjusted analyses, low BMI, moderate/severe anaemia and male sex were 
independent risk factors for mortality (Table 2). 
• HBV viral load did not have an impact on 1-year mortality among HIV/HBV-
coinfected individuals on TDF-containing ART.
Conclusions
• Early mortality of HIV/HBV-coinfected individuals on ART is very high in SSA, 
especially in rural settings, where access to care and treatment adherence may 
be reduced.
• Tracing of patients LTFU is needed if precise mortality estimates are to be 
obtained in rural SSA clinics. 
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581
Rural Mozambique Urban Zambia p-value
N=78 N=184 
Female (%) 47 (60.3) 76 (41.3) <0.001
Median age in years (IQR) 30 (25-39) 34 (28-39) 0.14
Median BMI (IQR) 19.5 (18.2- 21.6) 20.2 (18.6-23.1) 0.11
Median CD4 cells/μl (IQR) 232 (122-539) 208 (97-351) 0.03
WHO stage 3 or 4 (%) 33 (42.3) 74 (41.6) 0.50
Median ALT (IQR) 31 (19-59) 23 (15-40) 0.04
Moderate to severe anemia (%) 34 (56.7) 43 (25.3) <0.001
HBV genotype (%)
A1
E
Other
68 ()
14 ()
41 ()
50 ()
<0.001
HBV viral load >20,000UI/ml (%) 38 (52.8) 77 (45) 0.17
HR (95% CI) P-value aHR (95% CI) p-value
Origin (ref: Moz) 0.49 (0.23-1.04) 0.06 1.56 (0.51-4.81) 0.43
Male sex 3.36 (1.36-8.35) 0.01 4.00 (1.07-15.01) 0.04
Moderate/severe
anemia 6.50 (2.58-16.38) <0.001 8.64 (2.35-31.78) 0.001
CD4<200/µl 2.22 (0.94-5.23) 0.07 0.84 (0.29-2.49) 0.76
Age in years 1.04 (1.00-1.07) 0.05 1.01 (0.97-1.07) 0.52
BMI 0.75 (0.64-0.88) <0.001 0.72 (0.57-0.91) 0.01
HBV Viral load > 
20,000 IU/ml 0.96 (0.42-2.23) 0.93 - -
ALT 1.00 (0.98-1.01) 0.61 - -
WHO stage 3 or 4 2.06 (0.96-4.45) 0.06 0.82 (0.30-2.31) 0.72
HR: hazard ratios, aHR: adjusted hazard ratios, CI: confidence interval, BMI: body mass index, ALT: alanine 
aminotransferase
